Aytu Biopharma AYTU Cash Flow Statement (2010-2026)

NASDAQ AYTU
$2.15 -0.04 (-1.83%)
As of: Sep 9, 2026 · 2:18 PM EDT
Reported Financials

Aytu Biopharma Quarterly Cash Flow Statement

Periods 61 quarters
Latest Mar 2026

Aytu Biopharma reported cash from operations of -$4.18M and free cash flow of -$4.18M for the quarter ended Mar 2026, up 35.2% year over year. This cash flow statement covers 61 quarters of results from Nov 2010 through Mar 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Nov2010 Feb2011 May2011 Aug2011 Nov2011 Feb2012 May2012 Aug2012 Nov2012 Feb2013 May2013 Aug2013 Feb2014 May2014 Sep2014 Dec2014 Feb2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income
-18.74M-27.85M-11.55M-53.29M6.96M-0.70M-6.69M-7.20M1.12M-8.12M-0.24M-2.89M-0.30M1.47M0.81M3.99M-16.48M1.97M-10.58M-5.62M
Share-based CompensationStock Comp.
1.09M1.52M1.23M1.27M1.23M1.18M3.07M0.90M0.90M0.93M0.82M0.81M0.35M0.17M0.22M0.22M0.11M0.21M0.28M0.20M
Deferred Taxes
Gains from Investment SecuritiesGains Investment
-2.68M0.22M0.28M-1.26M0.55M0.07M
Asset Writedowns and ImpairmentWritedown
5.60M19.45M0.10M45.20M10.81M0.10M2.60M0.10M3.10M0.10M0.10M0.10M1.07M0.10M0.10M0.10M8.06M0.30M0.80M0.70M
Cash from OperationsCash from Ops.
-6.30M-3.80M-8.81M-9.12M-7.09M-9.15M-2.45M-2.90M9.37M-0.21M-0.14M-0.25M-0.79M-1.19M2.90M-6.46M2.80M-0.62M3.67M-4.18M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
-0.16M-0.16M-0.17M0.10M0.14M0.14M0.17M0.10M0.15M0.15M0.15M0.16M0.13M0.03M0.03M0.03M0.03M0.03M0.03M0.03M
Depreciation & Amortization (CF)Dep. & Amort.
3.32M2.68M2.67M2.57M2.22M2.30M2.21M2.19M2.12M2.23M1.79M2.69M1.94M1.43M1.34M
Change in Working Capital
Change in ReceivablesChange Receivables
0.22M-6.53M1.34M4.54M-5.89M6.21M-2.38M8.50M-5.18M1.68M-0.12M-1.03M-5.73M-0.48M2.27M10.51M-4.67M2.07M-2.30M-6.43M
Change in InventoryChange Inventory
-7.18M0.18M0.39M-0.66M-1.21M2.10M0.08M0.80M0.62M1.12M0.68M1.01M2.01M-0.33M-0.63M0.06M0.52M-1.06M-0.61M-0.54M
Change in Account PayablesChange Payables
2.91M-9.89M6.58M-4.79M0.42M3.59M-4.42M4.56M-1.34M0.95M-4.01M0.85M0.13M3.14M-1.81M0.40M-1.44M1.74M-1.08M-1.04M
Change in Accured ExpensesChange Accured Exp.
3.06M3.33M-3.94M1.87M-14.54M-3.48M2.47M8.04M-3.43M-5.17M1.27M0.16M-5.77M-4.97M7.31M1.61M-3.06M-1.64M3.46M-5.89M
Other Working Capital ChangesOther WC Changes
0.30M-0.15M0.10M-0.00M0.00M0.07M0.00M0.01M1.79M-3.74M-0.06M-0.04M0.04M-0.10M-0.20M-0.05M-0.17M-0.40M-0.18M-0.17M
Investing Activities
Capital ExpendituresCapex
-13.06M0.33M0.14M0.01M0.07M0.02M0.02M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.52M0.15M
Acquisitions
Cash from Investing ActivitiesCash from Investing
-2.43M-0.09M-3.05M-0.07M-0.04M0.04M-0.01M0.00M-0.15M-0.08M-0.17M-0.04M-0.03M0.38M0.14M-0.07M-3.02M-0.02M
Financing Activities
Other financing activitiesOther financing
-0.01M-0.00M-0.01M-0.05M
Cash from Financing ActivitiesCash from Financing
11.81M-5.46M6.59M1.52M-1.12M13.56M-1.86M2.58M-5.40M-2.73M-0.13M0.53M1.07M0.91M-2.76M4.30M12.99M2.30M-6.26M0.87M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.07M0.01M74.000.05M0.11M0.11M0.01M0.09M0.09M0.00M
Net Equity Issued and RepurchasedNet Equity Issued
12.80M0.31M4.52M7.88M-1.01M1.44M2.56M
Additional items
Change in Cash
3.11M-9.34M-5.28M-7.66M-8.25M4.45M-4.31M-0.32M3.81M-3.02M-0.43M0.23M0.25M0.10M0.29M-2.23M12.78M1.68M-2.60M-3.31M
Free Cash FlowFCF
6.76M-3.80M-8.81M-9.12M-7.09M-9.15M-2.45M-2.90M9.37M-0.21M-0.14M-0.25M-1.12M-1.33M2.90M-6.52M2.79M-0.62M3.66M-4.18M
Net Cash FlowNCF
3.09M-9.35M-5.27M-7.66M-8.25M4.45M-4.32M-0.32M3.81M-3.02M-0.43M0.23M0.25M0.10M0.29M-2.23M12.78M1.68M-2.60M-3.31M